SEC Form 3 · accession 0001144204-16-084414

SCICLONE PHARMACEUTICALS INC · SCLN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F14,750,116 shares of the common stock of Sciclone Pharmaceutical, Inc. (the "Company") are owned by GL Trade Investment Limited ("GL Trade"). GL China Opportunities Fund L.P. ("GL Fund") owns 100% of the voting interests in GL Trade. GL Capital Management GP L.P. ("GL Capital") is the general partner of GL Fund. GL Capital Management GP Limited ("GL Management") is the general partner of GL Capital. GL Partners Capital Management Limited owns 51% of the voting interests in GL Management. On the basis of the foregoing relationship, each of GL Trade, GL Fund, GL Capital, GL Management and GL Partners Capital Management Limited may be deemed a beneficial owner of the Company's common stock owned by GL Trade, but each such person disclaims beneficial ownership of such shares of common stock except to the extent of such person's pecuniary interest therein, if any.

Remarks

GL Management may be considered a member of a group beneficially owning more than 10% of the Company's common stock for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934. Neither the filing of this Form 3 nor any of its contents shall be deemed to constitute an admission by GL Management, GL Partners Capital Management Limited, or any other person that any such group exists and each of GL Management and GL Partners Capital Management Limited expressly disclaims the existence of such a group.